| Stereochemistry | RACEMIC |
| Molecular Formula | C23H26F4N2OS |
| Molecular Weight | 454.524 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CCCC2C3=CC=C(F)C=C3SC4=CC=C(C=C24)C(F)(F)F)CC1
InChI
InChIKey=BJWAPFORUPUXRJ-UHFFFAOYSA-N
InChI=1S/C23H26F4N2OS/c24-17-4-5-19-18(2-1-7-28-8-10-29(11-9-28)12-13-30)20-14-16(23(25,26)27)3-6-21(20)31-22(19)15-17/h3-6,14-15,18,30H,1-2,7-13H2
| Molecular Formula | C23H26F4N2OS |
| Molecular Weight | 454.524 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
PubMed
Patents
Sample Use Guides
Teflutixol has been administered for 4 weeks to 21 patients [12 schizophrenics, 6 patients with obsessive, compulsive neurosis (OCN), 2 patients with affective psychosis (AP), and one patient with paranoic reactions (PR)]. The maximum daily dose varied between 0.5 mg and 4 mg administered once in the morning.
Route of Administration:
Oral
